Aveo and Biodesix Stop Trials of Ficlatuzumab for Acute Myeloid Leukemia

Aveo and Biodesix have decided to stop all trials of their hepatocyte growth factor inhibitory antibody ficlatuzumab for acute myeloid leukemia (AML), citing the growing COVID-19 (coronavirus) pandemic.

The companies have halted the follow-up phase II CyFi-2 study, which was comparing high-dose cytarabine with or without ficlatuzumab with high-dose cytarabine alone in patients with relapsed or refractory AML.

“This decision is being taken due to the urgent shift among clinical sites toward efforts to combat the COVID-19 pandemic, which has impacted the feasibility of completing the study within the shelf-life of the current ficlatuzumab clinical trial supply. The study has not yet begun patient enrollment,” Aveo said in a brief statement.

Sources: Aveo press release, March 27, 2020; Fierce Biotech, March 30, 2020.